Administrative Core

行政核心

基本信息

  • 批准号:
    10517805
  • 负责人:
  • 金额:
    $ 14.05万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-21 至 2027-07-31
  • 项目状态:
    未结题

项目摘要

The ROBIN Administrative Core (AC) provides administrative and communication infrastructure to the ROBIN grant. Led by the three P.I.s, the AC is supported by an executive committee, composed by the leaders of the Cores, of the Molecular Characterization Trial (MCT) and of the scientific projects. The AC has a prestigious External Advisory Board (EAB), with members who represent all the disciplines and expertise relevant to this ROBIN. A team of experienced patients advocates, completes the organizational chart. An Executive Director will be recruited if the ROBIN is funded, in charge of maintaining communication and coordination of all ROBIN activities. To this scope the ROBIN Tracker will be introduced, adapted from an IT tool developed at Weill Cornell Medicine for electronic communication of activities and tasks of large grants (like SPORE or PPG). An important role of the AC is to develop a semestral evaluation plan and share it with the EAB, and if necessary, at ad hoc meetings when important decisions need to be made. Metrics of success will include the timely achievement of completion of MTAs and other legal steps to enable transfer between academic institutions of research specimens in the US, and of research data both in the US and Europe. Planned accruals to the MCT, generation of preliminary data from the scientific projects, and successful integration of trainees within the ROBIN programs are additional metrics of success. The iterative nature of ROBIN will also be assessed, as it is expected that the results of the first MCT and the associated scientific projects (converged with the feedback and results from the other centers in the ROBIN network) will inspire the design of one or more new MCT, around year 3. These new MCT will be implemented during the last two years of the award through the existing Immunology and Radiation Oncology Network (IRON) that will run the proposed first MCT. Another important role of the AC consists of assessing the Cross Training Core (CTC). While metrics of success of the CTC are defined in detail in its planned self-assessment, the AC will monitor the CTC to ensure a harmonious integration of the different disciplines and expertise that characterize ROBIN and are indispensable to a cross training in Radiation and Immunity, the overarching theme of this ROBIN proposal. A central duty of the AC is to identify potential collaborations within and beyond the ROBIN network and participate in the process of actualizing the restricted fund pilot projects program of the ROBIN network. The ROBIN newsletter proposed in the CTC, with distribution across the network will advertise the RFA. In addition, each of the ten academic institutions involved in this ROBIN will use their internal communication mechanisms to solicit applications. We expect the applications to be evaluated by a committee formed by representatives of each funded ROBIN. The AC will select representation from this ROBIN, based on the need of the committee, with consideration to ensure its diversity (gender balance, diversity of expertise and seniority, etc.). Finally, the AC leaders will participate in the executive activities of the ROBIN network and will be the link for bidirectional communication between this ROBIN and the rest of the network.
ROBIN 管理核心 (AC) 为 ROBIN 提供管理和通信基础设施 授予。审计委员会由三位 P.I. 领导,并得到一个执行委员会的支持,该执行委员会由各委员会的领导人组成 分子表征试验 (MCT) 和科学项目的核心。 AC 拥有享有盛誉的 外部顾问委员会 (EAB),其成员代表与此相关的所有学科和专业知识 罗宾。由经验丰富的患者组成的团队倡导,完成组织结构图。执行董事 如果ROBIN获得资助,将被招募,负责维护所有ROBIN的沟通和协调 活动。为此,将引入 ROBIN 跟踪器,该跟踪器改编自威尔康奈尔大学开发的 IT 工具 用于大笔赠款活动和任务的电子通信的医学(如 SPORE 或 PPG)。一个重要的 AC 的作用是制定学期评估计划并与 EAB 共享,如有必要,可临时共享 需要做出重要决定时召开的会议。成功的衡量标准将包括及时实现 完成 MTA 和其他法律步骤,以实现学术研究机构之间的转移 美国的标本以及美国和欧洲的研究数据。 MCT 的计划应计费用,发电 科学项目的初步数据以及受训者成功融入 ROBIN 计划 是衡量成功的附加指标。 ROBIN 的迭代性质也将被评估,因为预计 第一次 MCT 和相关科学项目的结果(与来自 ROBIN 网络中的其他中心)将在第 3 年左右激发一个或多个新 MCT 的设计。这些新的 MCT 将在获奖后的最后两年通过现有的免疫学和放射学实施 肿瘤学网络 (IRON) 将运行拟议的第一个 MCT。审计委员会的另一个重要作用包括 评估交叉训练核心(CTC)。虽然 CTC 的成功指标在其计划中详细定义 自我评估后,审计委员会将监督 CTC,以确保不同学科和领域的和谐整合。 ROBIN 的专业知识对于辐射和免疫领域的交叉培训是不可或缺的, ROBIN 提案的总体主题。审计委员会的核心职责是确定内部潜在的合作 并超越ROBIN网络,参与限制性基金试点项目的实施过程 ROBIN 网络的程序。 CTC 提议的 ROBIN 时事通讯,并通过网络分发 将为 RFA 做广告。此外,参与本次 ROBIN 的十个学术机构中的每一个都将使用他们的 征求申请的内部沟通机制。我们希望这些应用程序能够由 由每个资助的 ROBIN 的代表组成的委员会。 AC 将从该 ROBIN 中选择代表, 根据委员会的需要,并考虑确保其多样性(性别平衡、成员多样性) 专业知识和资历等)。最后,AC领导将参与ROBIN的执行活动 网络,并将成为该 ROBIN 与网络其余部分之间双向通信的链接。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Silvia C. Formenti其他文献

Emerging evidence for adapting radiotherapy to immunotherapy
适应免疫疗法的放疗新证据
  • DOI:
    10.1038/s41571-023-00782-x
  • 发表时间:
    2023-06-06
  • 期刊:
  • 影响因子:
    82.200
  • 作者:
    Lorenzo Galluzzi;Molykutty J. Aryankalayil;C. Norman Coleman;Silvia C. Formenti
  • 通讯作者:
    Silvia C. Formenti
Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking?
  • DOI:
    10.1186/s40425-016-0133-1
  • 发表时间:
    2016-05-17
  • 期刊:
  • 影响因子:
    10.600
  • 作者:
    Sandra Demaria;Silvia C. Formenti
  • 通讯作者:
    Silvia C. Formenti
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts
  • DOI:
    10.1186/s40425-016-0191-4
  • 发表时间:
    2016-12-01
  • 期刊:
  • 影响因子:
    10.600
  • 作者:
    Sonja Althammer;Keith Steele;Marlon Rebelatto;Tze Heng Tan;Tobias Wiestler;Guenter Schmidt;Brandon Higgs;Xia Li;Li Shi;Xiaoping Jin;Joyce Antal;Ashok Gupta;Koustubh Ranade;Gerd Binning;Joaquim Bellmunt;Ronald de Wit;David J. Vaughn;Yves Fradet;Jae Lyun Lee;Lawrence Fong;Nicholas J. Vogelzang;Miguel A. Climent;Daniel P. Petrylak;Toni K. Choueiri;Andrea Necchi;Winald Gerritsen;Howard Gurney;David I. Quinn;Stéphane Culine;Cora N. Sternberg;Yabing Mai;Markus Puhlmann;Rodolfo F. Perini;Dean F. Bajorin;Padmanee Sharma;Margaret K. Callahan;Emiliano Calvo;Joseph W. Kim;Filipo de Braud;Patrick A. Ott;Petri Bono;Rathi N. Pillai;Michael Morse;Dung T. Le;Matthew Taylor;Pavlina Spilliopoulou;Johanna Bendell;Dirk Jaeger;Emily Chan;Scott J. Antonia;Paolo A. Ascierto;Delphine Hennicken;Marina Tschaika;Alex Azrilevich;Jonathan Rosenberg;Ofer Levy;Christopher Chan;Gady Cojocaru;Spencer Liang;Eran Ophir;Sudipto Ganguly;Amir Toporik;Maya Kotturi;Tal Fridman Kfir;Benjamin M. Murter;Kathryn Logronio;Liat Dassa;Ling Leung;Shirley Greenwald;Meir Azulay;Sandeep Kumar;Zoya Alteber;Xiaoyu Pan;Arthur Machlenkin;Yair Benita;Andrew W. Drake;Ayelet Chajut;Ran Salomon;Ilan Vankin;Einav Safyon;John Hunter;Zurit Levine;Mark White;Rom Leidner;Hyunseok Kang;Robert Haddad;Neil H. Segal;Lori J. Wirth;Robert L. Ferris;F. Stephen Hodi;Rachel E. Sanborn;Thomas F. Gajewski;William Sharfman;Dan McDonald;Shivani Srivastava;Xuemin Gu;Penny Phillips;Chaitali Passey;Tanguy Seiwert;Tsadik Habtetsion;Gang Zhou;Donastas Sakellariou-Thompson;Cara Haymaker;Caitlin Creasy;Mark Hurd;Naohiro Uraoka;Jaime Rodriguez Canales;Scott Koptez;Patrick Hwu;Anirban Maitra;Chantale Bernatchez;Scott M. Coyle;Kole T. Roybel;Levi J. Rupp;Stephen P. Santoro;Stephanie Secrest;Michael Spelman;Hanson Ho;Tina Gomes;Tiffany Tse;Chia Yung-Wu;Jack Taunton;Wendell Lim;Peter Emtage;Tarsem Moudgil;Carmen Ballesteros-Merino;Traci Hilton;Christopher Paustian;Rom Leidner;David Page;Walter Urba;Bernard Fox;Bryan Bell;Ashish Patel;Tove Olafsen;Daulet Satpayev;Michael Torgov;Filippo Marchioni;Jason Romero;Ziyue Karen Jiang;Charles Zamilpa;Jennifer S. Keppler;Alessandro Mascioni;Fang Jia;Chen-Yu Lee;Jean Gudas;Ryan J. Sullivan;Yujin Hoshida;Theodore Logan;Nikhil Khushalani;Anita Giobbie-Hurder;Kim Margolin;Joanna Roder;Rupal Bhatt;Henry Koon;Thomas Olencki;Thomas Hutson;Brendan Curti;Shauna Blackmon;James W. Mier;Igor Puzanov;Heinrich Roder;John Stewart;Asim Amin;Marc S. Ernstoff;Joseph I. Clark;Michael B. Atkins;Howard L. Kaufman;Jeffrey Sosman;Sabina Signoretti;David F. McDermott;Abraham A. Anderson;Igor Puzanov;Mohammed M. Milhem;Robert H. I. Andtbacka;David Minor;Kevin S. Gorski;Daniel M. Baker;Omid Hamid;Howard L. Kaufman;Emmanuel Akporiaye;Brendan Curti;Yoshinobu Koguchi;Rom Leidner;Kim Sutcliffe;Kristie Conder;Walter Urba;Thomas Marron;Nina Bhardwaj;Linda Hammerich;Fiby George;Seunghee Kim-Schulze;Tibor Keler;Tom Davis;Elizabeth Crowley;Andres Salazar;Joshua Brody;Arta Monjazeb;Megan E. Daly;Jonathan Riess;Tianhong Li;William J. Murphy;Karen Kelly;Zhiwei Hu;Rulong Shen;Amanda Campbell;Elizabeth McMichael;Lianbo Yu;Bhuvaneswari Ramaswam;Cheryl A. London;Tian Xu;William Carson;Kathleen M. Kokolus;Elizabeth A. Repasky;Todd D. Schell;Joseph D. Drabick;David J. Messenheimer;Shawn Jensen;Bernard Fox;Mark Rubinstein;Kristina Andrijauskaite;Marzena Swiderska-syn;Kristin Lind;Agnes Choppin;Marina K. Roell;John Wrangle;Kristina Andrijauskaite;Marzena Swiderska-syn;Peter Rhode;Hing Wong;Mark Rubinstein;Shamim Ahmad;Mason Webb;Rasha Abu-Eid;Rajeev Shrimali;Vivek Verma;Atbin Doroodchi;Zuzana Berrong;David Yashar;Raed Samara;Mikayel Mkrtichyan;Samir Khleif;Steven Powell;Mark Gitau;Christopher Sumey;Andrew Terrell;Michele Lohr;Ryan K. Nowak;Steven McGraw;Ash Jensen;Miran Blanchard;Kathryn A. Gold;Ezra E. W. Cohen;Christie Ellison;Lora Black;John Lee;William Chad Spanos;Erik Wennerberg;Emily Schwitzer;Claire Lhuillier;Graeme Koelwyn;Rebecca Hiner;Lee Jones;Sandra Demaria;Vandeveer Amanda;John W. Greiner;Jeffrey Schlom;Michelle Bookstaver;Christopher M. Jewell;Christopher Paustian;Andrew Gunderson;Brian Boulmay;Rui Li;Bradley Spieler;Kyle Happel;Tarsem Moudgil;Zipei Feng;Carmen Ballesteros-Merino;Christopher Dubay;Brenda Fisher;Yoshinobu Koguchi;Sandra Aung;Eileen Mederos;Carlo B. Bifulco;Michael McNamara;Keith Bahjat;William Redmond;Augusto Ochoa;Hong-Ming Hu;Adi Mehta;Fridtjof Lund-Johansen;Bernard Fox;Walter Urba;Rachel E. Sanborn;Traci Hilton;Frank Bedu-Addo;Greg Conn;Michael King;Panna Dutta;Robert Shepard;Mark Einstein;Sylvia Adams;Ena Wang;Ping Jin;Yelena Novik;Debra Morrison;Ruth Oratz;Franco M. Marincola;David Stroncek;Judith Goldberg;Sandra Demaria;Silvia C. Formenti;Jérôme Galon;Bernhard Mlecnik;Florence Marliot;Fang-Shu Ou;Carlo B. Bifulco;Alessandro Lugli;Inti Zlobec;Tilman T. Rau;Iris D. Nagtegaal;Elisa Vink-Borger;Arndt Hartmann;Carol Geppert;Michael H. Roehrl;Prashant Bavi;Pamela S. Ohashi;Julia Y. Wang;Linh T. Nguyen;SeongJun Han;Heather L. MacGregor;Sara Hafezi-Bakhtiari;Bradley G. Wouters;Yutaka Kawakami;Boryana Papivanova;Mingli Xu;Tomonobu Fujita;Shoichi Hazama;Nobuaki Suzuki;Hiroaki Nagano;Kiyotaka Okuno;Kyogo Itoh;Eva Zavadova;Michal Vocka;Jan Spacek;Lubos Petruzelka;Bohuslav Konopasek;Pavel Dundr;Helena Skalova;Toshihiko Torigoe;Noriyuki Sato;Tomohisa Furuhata;Ichiro Takemasa;Marc Van den Eynde;Anne Jouret-Mourin;Jean-Pascal Machiels;Tessa Fredriksen;Lucie Lafontaine;Bénédicte Buttard;Sarah Church;Pauline Maby;Helen Angell;Mihaela Angelova;Angela Vasaturo;Gabriela Bindea;Anne Berger;Christine Lagorce;Prabhu S. Patel;Hemangini H. Vora;Birva Shah;Jayendrakumar B. Patel;Kruti N. Rajvik;Shashank J. Pandya;Shilin N. Shukla;Yili Wang;Guanjun Zhang;Giuseppe V. Masucci;Emilia K. Andersson;Fabio Grizzi;Luigi Laghi;Gerardo Botti;Fabiana Tatangelo;Paolo Delrio;Gennaro Cilberto;Paolo A. Ascierto;Franco Marincola;Daniel J. Sargent;Bernard A. Fox;Alain Algazi;Katy Tsai;Michael Rosenblum;Prachi Nandoskar;Robert H. I. Andtbacka;Amy Li;John Nonomura;Kathryn Takamura;Mary Dwyer;Erica Browning;Reneta Talia;Chris Twitty;Sharron Gargosky;Jean Campbell;Carmen Ballesteros-Merino;Carlo B. Bifulco;Bernard Fox;Mai Le;Robert H. Pierce;Adil Daud;Robyn Gartrell;Douglas Marks;Edward Stack;Yan Lu;Daisuke Izaki;Kristen Beck;Dan Tong Jia;Paul Armenta;Ashley White-Stern;Yichun Fu;Zoe Blake;Howard L. Kaufman;Bret Taback;Basil Horst;Yvonne M. Saenger;Steven Leonardo;Keith Gorden;Ross B. Fulton;Kathryn Fraser;Takashi O. Kangas;Richard Walsh;Kathleen Ertelt;Jeremy Graff;Mark Uhlik;Jennifer S. Sims;Liang Lei;Takashi Tsujiuchi;Jeffrey N. Bruce;Peter Canoll;Anthony W Tolcher;Evan W Alley;Gurunadh Chichili;Jan E Canoll;Paul Moore;Ezio Bonvini;Syd Johnson;Sadhna Shankar;James Vasselli;Jon Wigginton;John Powderly
  • 通讯作者:
    John Powderly
Radiosensitivity of skin fibroblasts from patients with aids-related Kaposi's sarcoma
  • DOI:
    10.1016/0360-3016(93)90929-p
  • 发表时间:
    1993-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Colin K. Hill;Silvia C. Formenti;Linda Y. Chak;Parkash S. Gill;Alexandra M. Levine;Zbigniew Petrovich
  • 通讯作者:
    Zbigniew Petrovich
Optimizing the Tumor Response to Ionizing Radiation and Immunotherapy by Blocking VEGF
  • DOI:
    10.1016/j.ijrobp.2008.06.524
  • 发表时间:
    2008-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Karsten A. Pilones;Silvia C. Formenti;Sandra Demaria
  • 通讯作者:
    Sandra Demaria

Silvia C. Formenti的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Silvia C. Formenti', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10708052
  • 财政年份:
    2022
  • 资助金额:
    $ 14.05万
  • 项目类别:
PSMA/MR-guided Stereotactic Body Radiotherapy for High Risk Prostate Cancer
PSMA/MR 引导的立体定向放射治疗高危前列腺癌
  • 批准号:
    10440533
  • 财政年份:
    2020
  • 资助金额:
    $ 14.05万
  • 项目类别:
GammabeamX200 Preclinical Research Irradiator
GammabeamX200 临床前研究辐照器
  • 批准号:
    7795491
  • 财政年份:
    2010
  • 资助金额:
    $ 14.05万
  • 项目类别:
Breast Cancer
乳腺癌
  • 批准号:
    7714197
  • 财政年份:
    2008
  • 资助金额:
    $ 14.05万
  • 项目类别:
CLINICAL TRIAL: INDIVIDUALIZED TX OF BREAST CANCER BASED ON TUMOR MOLECULAR CHAR
临床试验:基于肿瘤分子碳的乳腺癌个体化治疗
  • 批准号:
    7718400
  • 财政年份:
    2008
  • 资助金额:
    $ 14.05万
  • 项目类别:
BI-WEEKLY TAXOL & RT IN ANDROGEN ABLATED ADVANCED PROSTATE CANCER
双周紫杉醇
  • 批准号:
    7605686
  • 财政年份:
    2007
  • 资助金额:
    $ 14.05万
  • 项目类别:
INDIVIDUALIZED TX OF BREAST CANCER BASED ON TUMOR MOLECULAR CHARACTERISTICS
基于肿瘤分子特征的乳腺癌个体化治疗
  • 批准号:
    7605704
  • 财政年份:
    2007
  • 资助金额:
    $ 14.05万
  • 项目类别:
RESPONSE, RESISTANCE AND METASTASIS OF LOCALLY-ADVANCED BREAST CANCER (LABC)
局部晚期乳腺癌 (LABC) 的反应、抵抗和转移
  • 批准号:
    7605773
  • 财政年份:
    2007
  • 资助金额:
    $ 14.05万
  • 项目类别:
INDIVIDUALIZED TX OF BREAST CANCER BASED ON TUMOR MOLECULAR CHARACTERISTICS
基于肿瘤分子特征的乳腺癌个体化治疗
  • 批准号:
    7378275
  • 财政年份:
    2006
  • 资助金额:
    $ 14.05万
  • 项目类别:
BI-WEEKLY TAXOL & RT IN ANDROGEN ABLATED ADVANCED PROSTATE CANCER
双周紫杉醇
  • 批准号:
    7378246
  • 财政年份:
    2006
  • 资助金额:
    $ 14.05万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 14.05万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 14.05万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 14.05万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 14.05万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 14.05万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 14.05万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 14.05万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 14.05万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 14.05万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 14.05万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了